Opzelura Experience Study
NCT07661979
·
clinicaltrials.gov ↗
PHASE4
Phase
NOT_YET_RECRUITING
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Atopic Dermatitis
Interventions
DRUG:
ruxolitinib
DRUG:
ruxolitinib and an Eczema Action Plan
Sponsor
Wake Forest University Health Sciences